Fundz

Memgen reported raising $950,000 in an initial SEC Form D filing, from an offering of $10 Million

PRIVATEDec 10, 2024$950K of $10M raised

Amount Raised

$950,000

$950,000 sold, per SEC Form D (first sale Nov 26, 2024)

Round Type

Venture

HoustonBiotechnology

Quick answer

Memgen, Inc. raised $950,000 in a funding round, dated November 26, 2024. Memgen, Inc. is based in Houston, Texas, United States.

How much did Memgen, Inc. raise?
Memgen, Inc. raised $950,000 in a funding round on November 26, 2024.
What does Memgen, Inc. do?
Memgen is developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from COVID-19 and other diseases.
Where is Memgen, Inc. based and how big is it?
Memgen, Inc. is based in Houston, Texas, United States.
Who are the decision-makers at Memgen, Inc?
Fundz holds 1 contact at Memgen, Inc., including the Executive Officer, Director. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Memgen, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Windward Bio raised $200M (Series A) on January 10, 2025.
  • Light Horse Therapeutics raised $62M (Series A) on January 10, 2025.
  • Numab Therapeutics raised $55M (Series C) on January 10, 2025.
  • RhyGaze raised $86M (Series A) on January 10, 2025.
  • Kardigan raised $300M (Series A) on January 10, 2025.
  • Ouro Medicine raised $120M (Series A) on January 10, 2025.

Who to call at Memgen, Inc., and when

A new round usually means Memgen, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Memgen, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Memgen, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Memgen, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Memgen, Inc.

Location

12 GREENWAY PLAZA

Houston, Texas, United States

About

Memgen is developing viral immunotherapies to harness the power of the immune system to potentially cure cancer and to protect people from COVID-19 and other diseases. The Company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has already been tested in clinical trials and has demonstrated the ability to elicit powerful, antigen-specific immune responses. The Company’s lead cancer immunotherapy, MEM-288, was developed in collaboration with Moffitt Cancer Center. It is an oncolytic virus engineered to selectively target cancer cells and to supercharge the immune system through expression of two unique and powerful immune modulators: MEM40 and the powerful cytokine interferon beta. MEM-288 generates a strong systemic anti-tumor immune response following intra-tumoral vaccination in multiple tumors. Memgen expects to begin clinical testing with MEM-288 in advanced cancers in the current year. Memgen's COVID-19 vaccine, MemVax, is an adjuvant designed to be used in combination with other COVID-19 vaccines to generate a strong, durable immune response. MemVax is a highly specific immune stimulant that can work with COVID-19 antigens across a range of delivery approaches. Memgen has over 100,000 doses of MemVax ready to go into clinical trials, and an active file with the US FDA. Memgen plans to soon begin clinical trials of MemVax in collaboration with other companies developing complementary COVID-19 vaccines.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Memgen, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMark C., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Memgen, Inc.'s next move

See what Strategic adds

Memgen, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.